Abstract: Structural modifications of the side-chain of vitamin D lead potentially to analogs in which a separation is effected between calcemic activity and cellular differentiation. Vitamin D analogs are used clinically for diseases involving cell proliferation. We have discovered an important lead compound, namely, 24-@)-ethylla-hydroxyvitamin D3 (5d) also called la-hydroxyvitamin Ds, which is active as an anticancer agent. The renal metabolism of 5d results in hydroxylation at c26 (C27), to yield 9 or 10. Synthesis of this metabolite is presented.
BACKGROUND
la,25-Dihydroxyvitamin D3 (1) is the hormonally active form of vitamin D3 and it is essential for the control of calcium homeostasis in the animals and humans. Recently, a striking development has occurred in the area of vitamin D. The main focus of many vitamin D studies has shifted from the more or less classical calcium homeostasis perspective to the regulation of a multitude of other cellular processes. This shift may be traced basically to the diversity of receptors for la,25-dihydroxyvitamin D3 (1)l which have been discovered throughout the human body. In addition to the more typical sites of action, i.e., intestinal mucosa, bone and kidney, other calcium binding proteins have been discovered in rat brain, spinal cord and hematopoietic cells. la,25-Dihydroxyvitamin D3 (1) plays an important role in the area of cancer therapy because of its effect upon three phenomena: cellular induction of differentiation, suppression of cellular proliferation, and both balanced against reduced or low calcemic activity.
The central synthetic problem in vitamin D chemistry is obtention of an analog in which a separation exists between calcemic activity and cellular differentiation activity and cancer agents. At the levels needed for in vivo antileukemic agents, la,25-dihydroxyvitamin D3 (1) induces toxic blood levels of calcium. Thus, a la,25-dihydroxyvitamin D analog in which the side chain is elongated by one carbon atom shows a differentiation activity for leukemia cells about ten times greater than 1 itself but this homolog is approximately equipotent to 1 in calcemic activity.2 The differentiati0n:calcemic activity ratio is improved but this homolog could not be called selective. Addition of two extra carbon atoms, to form a bis-homo analog, namely, 24-bishomo-la,25-dihydroxyvitamin D3 (6) leads to a superior compound2 which is devoid of calcemic activity at concentrations where malignant cell antiproliferative and cell differentiation activity are potent.
These side-chain modified analogs are synthesized by a number of different routes, all of which basically involve cleavage of the existing side-cahin from a precursor vitamin D and the reattachment of the appropriate synthon via Wittig, Julia or Grignard coupling. In our work we followed a different approach.
Nature provides a rich array of side-chain alkylated cholesteryl derivatives. These encompass either a methyl or ethyl group at C24 and an E-double bond at C22-23, i.e. 2a-d, 4a-d. Each of these naturally occumng steroids could be converted into a la-hydroxyvitamin, i.e., 2a-d to 3a-d; 4a-d to 5a-d.
Vitamin Ds (24 R-ethyl vitamin D3) (8) was first reported over fifty years ago and was formed from irradiation of 7-dehydrositosterol (7) and showed no effect on blood serum calcium in the chicken.3~4 In a modern context this is a very important factor since lack of calcemic activity suggests the examination of the la-hydroxy analog i.e., 5d, as an anticancer agent. In fact it proved to be extremely active in blocking breast cancer. la-OH-D5 (5d) was shown to inhibit growth and induce differentiation in UISO-BCA-1 and UISO-BCA-4 human breast carcinoma cell lines.5 Furthermore la-OH-DS (5d) is non-calcemic.
The synthesis of la-OH-Ds (5d) which proceeds from stigmasterol (2c) is as follows: The oxidative metabolism of 5d in normal human liver cell HHOI proved interesting6 This system is capable of C25 and C27 hydroxylation. The stereochemistry of enzymatic hydroxylation at C a of the sidechain of vitamin D analogs, as in the case of la-OH-D2, affords la,24 S (OH)2D2.7 This involves retention of configuration at Cu. It would appear that the hydroxylation at C u is stereoselesctiveg and occurs with retentigin of configuration in the case of D2 and epi D4. In the case of D4 and D5 the substituent at C24 is reversed relative to D2 and epi-D4 and hydroxylation occurs at C25 (c26) (5a to 9 or 10). Since a new chiral center is created at C25 it becomes a synthetic problem to prepare the two c26 hydroxylated compounds related to vitamin D5 and determine which is the natural metabolite i.e., 9 or 10
The syntheses of 9 and 10 start from stigmasterol (2c) which is converted to the p-toluenesulfonate and solvolysis in methanol/ KOAc to yield the i-steroid 22E,24S-6~-methoxy-24-ethyl-3a,5a-cyclocholest-22-ene (6) which upon ozonolysis yielded aldehyde 11. Claisen rearrangements 14 to 16 and 15 to 16 provide the correct side-chain for 19 to 20. The C25 epimeric c26 (C27) hydroxylated stigmasterols are converted to the la-hydroxyvitamin D5 9 and 10 using the methods described earlier.
